Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Date:11/27/2007

CALGARY, Nov. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,300,650 entitled "Reovirus for the Treatment of Neoplasia." The claims describe methods of using the reovirus to treat cancers that have inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other factors. PKR is a host cellular protein responsible for preventing virus replication within a cell. Tumour cells lacking the activity of PKR are susceptible to reovirus replication and subsequently, cancer cell killing.

"This patent represents a significant expansion of our intellectual property portfolio," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "The claims cover additional pathways whereby tumours can become susceptible to reovirus infection and cell death."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...nty of Britain,s most,innovative technology compan...t the fifth annual SETsquared Partnership Showcase...George Street, London, from 8am on,Thursday, Octob...nnovators,in electronics, information technology, ...l give 10-minute presentations to an audience of,a...
(Date:10/10/2008)...da Pharmaceutical Company,Limited ("Takeda") today...ment Center, Inc., a wholly owned United States (U...S. Food and Drug Administration (FDA) will,not be ...Drug Application,(NDA) by the Prescription Drug Us... our most recent discussion with the FDA, it indic...
(Date:10/9/2008)...Pairing traditional quality,tools with innovations...g,are helping organizations reduce waste, meet cus...today,s market. At How Process Improvement Leaders...ality excellence,conference hosted by Best Practic...from leading companies shared results from recent ...
(Date:10/9/2008)...oss Life Sciences Industry -, ROCKLAND, Mass., Oc...e,of Merck KGaA, Darmstadt, Germany, announced tod... top employer in the biotechnology and,pharmaceuti... employers,across the life sciences., "We are hon...EMD Serono,as a leading place to work," said Bernh...
Breaking Biology Technology:Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 2Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 3FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes 2EMD Serono Named as a Top Employer by Science Magazine 2
... Part I of this series on e-discovery, we discus...rocedure, which require parties to address and res...lly stored information ("ESI"). Without a plan of ...o preserve relevant ESI, you may unnecessarily be ...ses how to minimize those risks and find safe harb...
...ison, Wis. - TrafficCast International , a globa...2 million in new angel funding in a round led by t... Angels Fund I of Madison and NEW Capital Fund ...incides with the release of TrafficCast,s signatur...estimates based on impact modeling of weather, inc...
...ison, Wis . - Paul Schneider, a director for the G...onal , has been elected to the board of TrafficCa...ital traffic data. , ,At Schneider National, Schne...nd pricing of more than $3.5 billion in annual rev... and a leading company in transportation logistics...
...ison, Wis. - Investments in early-stage Wisconsin...average size of each deal might point to some inte...utlined in a recent report titled Risk Capital in ...roduced by NorthStar Economics , the Wisconsin T...inancial Institutions . , ,While the total amount...
Other Biology Technology:Finding Safe Harbor in a sea of electronic discovery 2Finding Safe Harbor in a sea of electronic discovery 3TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund 2Breaking down Wisconsin's angel capital numbers 2Breaking down Wisconsin's angel capital numbers 3
(Date:10/10/2008)...In a groundbreaking study led by an eminent molecu...hers have discovered that as embryonic stem cells ... corresponding changes to the order in which DNA i...dge a critical knowledge gap for stem cell biologi...usly complex process by which DNA is repackaged du...
(Date:10/10/2008)...2008 The world,s top scientists and clinicians in...phia to present their latest research findings at ...f Human Genetics (ASHG) from Tuesday, November 11,...sylvania Convention Center., Founded in 1948, ASH...ion for human genetics,specialists worldwide, rep...
(Date:10/10/2008)...of Kyoto University and the Gladstone Institute of...tep forward in improving the possibilities for the... (iPS) cell technology. , Previously, Dr. Yamana...to become embryonic stem celllike using a cancer-c...to reprogram the cells, and a virus to transfer th...
(Date:10/10/2008)...nsula Medical School in Plymouth, UK, have carried...te exercise a day recommended to children from hea... problem of childhood obesity. , Their research ... journal "Archives of Diseases in Childhood." , ...as followed the development of over 200 children i...
Breaking Biology News(10 mins):Landmark study unlocks stem cell, DNA secrets to speed therapies 2Landmark study unlocks stem cell, DNA secrets to speed therapies 3The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia 2The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia 3The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia 4The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia 5Yamanaka eliminates viral vector in stem cell reprogramming 2Recommendations for children's exercise lacking say experts 2Obesity Related Inflammation Boosts Heart Risks 18540 1Obesity Related Inflammation Boosts Heart Risks 18540 2Weill Cornell receives funding to study creation of new elder abuse center 18537 1Weill Cornell receives funding to study creation of new elder abuse center 18537 2The cooperative view 3A New evidence suggests a symbiogenetic origin for the centrosome 3195 1The cooperative view 3A New evidence suggests a symbiogenetic origin for the centrosome 3195 2Veteran Behavioral Health Services Executive to Lead Mental Health Association of Southeastern Pennsylvania 18534 1Veteran Behavioral Health Services Executive to Lead Mental Health Association of Southeastern Pennsylvania 18534 2
...mbitious plan is under way in the ecological commu...successful river restoration. The plan is being le...pplied Ecology, which this month is publishing a s...ebate is a paper by 22 leading US river ecologists...ul river restoration. Their aim is to arrive at an...
...netic tool with the potential to identify which tr...eriously ill has worked consistently in a wide ran... hurdle to overcome before the method is routinely... , In a report published today (March 7) in the P...searchers from eight institutions, including the U...
...w study is providing scientists with a better unde...c leukemia (ALL) patients fail to respond to treat...ia point towards a positive treatment outcome. The...Cell, is likely to facilitate development of new s...failure for children with ALL. , Nearly 80% of chi...
...ounds found in plastic products used to wrap or co...possible cancer-causing agents because they can so...the food, especially after heating or when the pla... the National Institute of Environmental Health Sc...Philadelphia have demonstrated that two plasticize...
Other Biology News:Putting ecology back into river restoration 2Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia 2Compounds in plastic packaging act as environmental estrogens altering breast genes 2
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry.
Silencer Pre-designed siRNA, HPLC purified, annealed from Ambion
...y and reliably amplify unknown genomic DNA using ...le-free, ready-to use components, at an extraordin... are provided in each kit. The Locator Kit can be ...ns, bi-directional sequence extension of sequence-...
...finize and perform Heat Induced Antigen Retrieval ...sections mounted on glass microscope slides. Depar...n at the high temperature used in HIER (over 90deg...by detergent. Formaldehyde fixation impairs or tot...
Biology Products: